Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.
At one Ryan White clinic in Virginia, the likelihood of multiple health conditions increased over time.
The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.
HIV prevention drugs don’t seem to impact gender-affirming hormone levels, but the opposite might not be true for trans men.
HPV-related anal or genital warts were linked to progression to cancer in a large, long-term study of people with HIV.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
Contradicting a previous study, new data on injectable contraceptives suggest the vaginal microbiome may increase susceptibility to HIV.
People with HIV and ulcerative colitis or Crohn’s disease may need less IBD medication and have fewer hospitalizations.
Kenya has been using similar technology for three years. DC’s efforts are among the first in the United States.
Nearly eight years after Truvada’s approval for HIV prevention, primary care providers struggle to understand—and prescribe—the pill.
PrEPception, breast feeding and HIV trial participation are front and center in updated federal guidelines.
Researchers found that Truvada as pre-exposure prophylaxis greatly reduced HIV cases in both people on PrEP and those not on it.
Larger studies suggest people living with HIV might have a modestly higher risk of severe COVID-19, but much remains to be learned.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.